Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Therma Bright (OTCQB:TBRIF) has expanded its strategic partnership with Gen-X Med for the distribution of Venowave™ VW5 devices. This follows an initial 200-unit sale announced in April 2025, targeting specialized knee surgeons in the U.S. healthcare network.
The partnership focuses on the growing specialized knee surgery market segment, with Gen-X Med reporting positive patient outcomes from the initial deployment. The global compression therapy market, valued at $4.18 billion in 2024, is projected to reach $6.72 billion by 2033, growing at a CAGR of 7.30%.
Therma Bright (OTCQB:TBRIF) ha ampliato la partnership strategica con Gen-X Med per la distribuzione dei dispositivi Venowave VW5. Questo segue una vendita iniziale di 200 unità annunciata ad aprile 2025, rivolta a chirurghi specializzati del ginocchio nella rete sanitaria statunitense.
La collaborazione si concentra sul segmento di mercato in crescita relativo alla chirurgia specialistica del ginocchio, con Gen-X Med che riferisce esiti positivi dei pazienti dal primo impiego. Il mercato globale della terapia di compressione, valutato $4.18 miliardi nel 2024, è previsto raggiungere $6.72 miliardi entro il 2033, crescendo a un CAGR del 7.30%.
Therma Bright (OTCQB:TBRIF) ha ampliado su asociación estratégica con Gen-X Med para la distribución de los dispositivos Venowave VW5. Esto sigue a una venta inicial de 200 unidades anunciada en abril de 2025, dirigida a cirujanos especializados de rodilla en la red de atención médica de EE. UU.
La asociación se centra en el creciente segmento del mercado de cirugía de rodilla especializada, con Gen-X Med reportando resultados positivos en los pacientes desde la implementación inicial. El mercado global de la terapia de compresión, valorado en $4.18 mil millones en 2024, se proyecta que alcance $6.72 mil millones para 2033, creciendo a una tasa CAGR de 7.30%.
Therma Bright (OTCQB:TBRIF)은 Venowave VW5 기기의 유통을 위해 Gen-X Med와의 전략적 제휴를 확대했습니다. 이는 2025년 4월에 발표된 초기 200대 판매에 이어 미국 의료 네트워크의 전문 무릎 수술 의사를 대상으로 한 것입니다.
협력은 전문 무릎 수술 시장의 성장 부문에 중점을 두고 있으며, Gen-X Med는 초기 배치 이후 환자 결과가 긍정적이라고 보고했습니다. 글로벌 차압 치료 시장은 2024년 기준 $4.18십억 달러로 평가되었고, 2033년까지 $6.72십억 달러에 이를 것으로 예상되며 연평균 성장률(CAGR)은 7.30%입니다.
Therma Bright (OTCQB:TBRIF) a renforcé son partenariat stratégique avec Gen-X Med pour la distribution des dispositifs Venowave VW5. Cette démarche fait suite à une première vente de 200 unités annoncée en avril 2025, ciblant les chirurgiens spécialisés du genou au sein du réseau de soins américain.
Le partenariat se concentre sur le segment croissant du marché des chirurgies spécialisées du genou, Gen-X Med faisant état de résultats positifs chez les patients depuis le déploiement initial. Le marché mondial de la thérapie par compression, évalué à 4,18 milliards de dollars en 2024, devrait atteindre 6,72 milliards de dollars d'ici 2033, avec un taux de croissance annuel composé (CAGR) de 7,30%.
Therma Bright (OTCQB:TBRIF) hat seine strategische Partnerschaft mit Gen-X Med für den Vertrieb der Venowave VW5-Geräte ausgeweitet. Dies folgt auf den im April 2025 angekündigten ersten Verkauf von 200 Einheiten, der sich an spezialisierte Kniesurgeon im US-Gesundheitsnetz richtet.
Die Partnerschaft konzentriert sich auf das wachsende Segment des spezialisierten Knieoperation-Marktes, wobei Gen-X Med positive Patientenergebnisse aus dem ersten Einsatz meldet. Der globale Markt für Kompressionstherapie, im Jahr 2024 auf 4,18 Milliarden USD bewertet, soll bis 2033 6,72 Milliarden USD erreichen, bei einer CAGR von 7,30%.
Therma Bright (OTCQB:TBRIF) قد وسّعت شراكتها الاستراتيجية مع Gen-X Med لتوزيع أجهزة Venowave VW5. يأتي ذلك بعد بيع أولي لـ200 وحدة أُعلن عنه في أبريل 2025، يستهدف جراحي الركبة المتخصصين ضمن شبكة الرعاية الصحية الأمريكية.
تركّز الشراكة على قطاع جراحة الركبة المتخصص المتنامي، حيث أبلغت Gen-X Med عن نتائج إيجابية للمرضى منذ النشر الأول. السوق العالمي للعلاج بالضغط، المُقدَّر قيمته بـ $4.18 مليار في 2024، من المتوقع أن يصل إلى $6.72 مليار بحلول 2033، بمعدل نمو سنوي مركب قدره 7.30%.
Therma Bright (OTCQB:TBRIF) 已扩大与 Gen-X Med 的战略伙伴关系，负责 Venowave VW5 设备的分销。这是在2025年4月宣布的初始200台销售之后，面向美国医疗网络中的专科膝关节外科医生。
本次合作聚焦于增长中的专科膝关节手术市场领域，Gen-X Med 报告称自初始部署以来患者结果积极。全球压缩治疗市场在2024年的估值为 $4.18 十亿美元，预计到2033年将达到 $6.72 十亿美元，年复合增长率为 7.30%。
- None.
- None.
Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure. Specialized knee surgeries represent a high value and growing segment of the U.S. healthcare market.
"We are pleased to partner with Therma Bright in offering the Venowave™ VW5 to our doctor network," shared Beau Wood, President, Gen-X Med. "We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution."
Rob Fia, CEO of Therma Bright, added, "This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave™ offers significant advantages for patients and the U.S. healthcare system by reducing post-surgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value."
According to a November 2024 press announcement from Straits Research, the global compression therapy market was valued at
About the Venowave™ VW5
The Venowave™ VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated Durable Medical Equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by
About Gen-X Med
Gen-X Med is an Arlington, Texas-based distributor committed to providing healthcare professionals with specialized, vetted products and exceptional client care. The company's portfolio includes durable medical equipment (DME) products, with a focus on sourcing and providing the most qualified products and services to meet the needs of its clients.
Visit: http://www.genxmed.net/
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: (https://www.thermabright.com).
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on X:
https://x.com/Bright_Therma
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267679
FAQ
What is the recent partnership announcement between Therma Bright (TBRIF) and Gen-X Med?
What is the market size for compression therapy products like Therma Bright's Venowave?
How has the initial 200-unit Venowave sale performed for Therma Bright?
What is the strategic importance of the Gen-X Med partnership for TBRIF?
